LBA71 Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study). - Conteduca, V.; Brighi, N.; Gurioli, G.; Wetterskog, D.; Giunta, E.F.; Lolli, C.; Schepisi, G.; Chiuri, V.E.; Gasparro, D.; Zucali, P.A.; Virga, A.; Bondi, I.; et al. (Annals of Oncology, 2024)